Patents by Inventor Kevin LUK

Kevin LUK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230049455
    Abstract: RNA-guided programmable cytosine and adenine base editors are a powerful class of genome editing tool for the introduction of localized base transitions without generating a double-stranded DNA break. Base editors (BE) have an optimal window of activity relative to the PAM recognized by the Cas9 enzyme and these constructs are strand selective. Here we demonstrate that fusion of a programmable DNA-binding domain (pDBD) or another Cas9 orthologue to spCas9-BE, we can produce an RNA-programmable Cas9-BE-pDBD chimera or Cas9-BE-Cas9 chimeras with dramatically improved activities and increased targeting range. Cas9-pDBD or Cas9-Cas9 fusion base editors display an expanded targeting repertoire and achieve highly specific genome editing, which can be tailored to achieve extremely precise genome editing at nearly any genomic locus.
    Type: Application
    Filed: January 29, 2021
    Publication date: February 16, 2023
    Inventors: Scot A. Wolfe, Pengpeng Liu, Kevin Luk
  • Publication number: 20220186218
    Abstract: Provided herein are ribonucleoprotein (RNP) complexes comprising a DNA-targeting endonuclease Cas (CRISPR-associated) protein and a guide RNA (gRNA) that that targets and hybridizes to the ?-Globin gene. In one embodiment, the Cas protein is Cas9 and the gRNA comprises the sequence of SEQ ID NO: 1. In one embodiment, the Cas protein is Cas12a and the gRNA comprises the sequence of SEQ ID NO: 3.
    Type: Application
    Filed: January 24, 2020
    Publication date: June 16, 2022
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTS
    Inventors: Daniel E. BAUER, Shuqian XU, Scot A. WOLFE, Kevin LUK
  • Publication number: 20210047632
    Abstract: Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.
    Type: Application
    Filed: July 20, 2018
    Publication date: February 18, 2021
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTS
    Inventors: Daniel E. BAUER, Scot WOLFE, Mehmet Fatih BOLUKBASI, Benjamin ROSCOE, Pengpeng LIU, Kevin LUK, Yuxuan WU, Jing ZENG